AAV-loadable hypercompact ABEs developed by GenKOre

GenKOre (homepage: www.genkore.com) is a biotech spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is a government-invested research institute in Korea. It has platform business through highly efficient genome editing platform. They develop AAV/non-viral-based gene therapy and new plant varieties using its own genome editing technology. Previously, GenKOre developed a hypercompact CRISPR system with AAV delivery compatibility, coined TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology), which was published in Nature Biotechnology in 2021.

GenKOre (homepage: www.genkore.com) is a biotech spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is a government-invested research institute in Korea. It has platform business through highly efficient genome editing platform. They develop AAV/non-viral-based gene therapy and new plant varieties using its own genome editing technology. Previously, GenKOre developed a hypercompact CRISPR system with AAV delivery compatibility, coined TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology), which was published in Nature Biotechnology in 2021.

This new base-editing technology is expected to provide various in vivo treatment options for genetic diseases through AAV delivery. Alternatively, the ABE system is expected to harness the development of ex vivo gene-editing therapy targeting immune cells and hematopoietic stem cells.

The related article published on Nature Chemical Biology can be checked at: https://www.nature.com/articles/s41589-022-01077-5.

GenKOre website: www.genkore.com

Photo - https://mma.prnewswire.com/media/1870659/Gene_editing.jpg